Loading viewer...
earnings
Format: PDF earnings
Third quarter 2016 earnings presentation from a biopharmaceutical company developing prodrug product candidates. The presentation discusses clinical trial plans, regulatory approval strategies including FDA 505(b)(2) pathways and expedited review opportunities, and the company's intellectual property position.
investor_presentation
18 Pages
earnings
32 Pages
Avangrid, Inc.
Thermon Group Holdings Q1 FY2025 Earnings Presentation
earningsearnings
16 Pages
Thermon Group Holdings, Inc.
ICE 1Q23 Earnings Supplement – Q1 2023 Results
earningsearnings
22 Pages
Intercontinental Exchange